Introduction {#s0001}
============

Although vaccines have substantially reduced the rates of pneumococcal disease, each year, *S. pneumoniae* still causes more than 800,000 deaths worldwide in children under 5 y of age.[@cit0001] Currently marketed vaccines are based on polysaccharide capsular antigens from the most common strains.[@cit0002] Coverage, however, is incomplete because serotype circulation can vary between countries or regions,[@cit0003] and protection may eventually decrease due to serotype replacement.[@cit0004] Vaccines based on conserved pneumococcal proteins are therefore being investigated.[@cit0002]

Pneumococcal histidine triad protein D (PhtD) and pneumococcal choline-binding protein A (PcpA) are *S. pneumoniae* surface proteins that are being studied as candidate antigens for a pneumococcal protein vaccine. PhtD is a highly conserved virulence factor that induces an effective immune response in infected individuals.[@cit0008] The function of PcpA is less clear, although it may play a role in pneumococcal adherence.[@cit0014] Immunization with PhtD elicits protection against pneumococcal nasopharyngeal and lung colonization in mice[@cit0015] and reduces pneumococcal burden in primates.[@cit0018] Also, naturally acquired anti-PhtD antibodies protect mice against pneumococcal colonization.[@cit0014] A monovalent PhtD vaccine was shown to be well tolerated and immunogenic in a phase I trial,[@cit0019] and we have confirmed that the antibodies induced by the vaccine are functional in a mouse passive protection sepsis model.[@cit0020] Likewise, immunization with PcpA, another highly conserved surface protein,[@cit0021] has been shown to be protective in active immunization murine models of both sepsis and pneumonia.[@cit0022] Furthermore, expression of PcpA is increased in environments low in Mn^2+^, including serum and other internal sites.[@cit0022]

The safety and immunogenicity of a candidate bivalent PcpA-PhtD protein vaccine have been evaluated in a phase I trial in which 60 subjects were vaccinated twice 30 d apart with 10, 25, or 50 µg of each antigen.[@cit0024] Here, we tested sera from these subjects for the presence of functional antibodies using the same passive protection mouse model that we previously used to examine antibodies induced by a monovalent PhtD candidate vaccine.[@cit0020] We also investigated the relationship between activity in this passive protection model, serum anti-PhtD and anti-PcpA antibody concentrations, and activity in a bacterial surface binding assay.

Results {#s0002}
=======

Selection of sera {#s0002-0001}
-----------------

Sera were available from 60 subjects who had received the PhtD-PcpA candidate vaccine. Twenty pairs of pre- and post-immune samples were selected based on low activity of the pre-immune sample in the mouse passive protection model (≤ 1 of 5 mice surviving at day 4; Supplemental Fig. 1). In all cases, the post-immune serum protected more mice from death at day 4 than the matched pre-immune serum, and for 16 of 20, the difference was significant ([Table 1](#t0001){ref-type="table"}). Mean time to death was also longer in all cases with the post-immune serum than with the matched pre-immune serum and significantly longer in 18 of 20 cases. Furthermore, more mice overall were protected by post-immune sera than by pre-immune sera (84/100 vs. 4/100; p \< 0.0001). Figure 1.Relationship between post-vaccination anti-PcpA and anti-PhtD antibody concentrations and passive protection of mice. Shown are the relationships between survival at day 4 and post-vaccination anti-PcpA and anti-PhtD antibody concentrations (A), pre- and post-vaccination anti-PcpA concentrations (B), and pre- and post-vaccination anti-PhtD concentrations (C). Table 1.Activity of pre- and post-immune sera in the mouse passive protection model.   No. of mice surviving at day 4Time to death (h), mean ± standard deviationClinical trial subject no.Vaccine doseSerum dilution testedPre-immune serumPost-immune serumP-valuePre-immune serumPost-immune serumP-value1010 µg1:20050.00446 ± 11336 ± 00.0022310 µg1:20050.00449 ± 10336 ± 00.0026125 µg1:40040.02487 ± 46296 ± 890.0087025 µg1:40040.02471 ± 24291 ± 1000.0058025 µg1:40040.024154 ± 50282 ± 1200.0348425 µg1:40140.103134 ± 116291 ± 1000.0449425 µg1:20050.00446 ± 11336 ± 00.00210125 µg1:20030.08347 ± 10233 ± 1440.01610525 µg1:40050.00446 ± 11336 ± 00.00210850 µg1:20050.004100 ± 132336 ± 00.01311050 µg1:40040.02451 ± 21282 ± 1210.00711250 µg1:40020.22251 ± 13193 ± 1420.05311550 µg1:40120.50104 ± 130161 ± 1600.78711750 µg1:20050.00466 ± 29336 ± 00.00212150 µg1:20150.024115 ± 127336 ± 00.01312250 µg1:20040.02452 ± 15282 ± 1210.00912350 µg1:40040.02441 ± 0278 ± 1300.00312450 µg1:20050.00484 ± 36336 ± 00.00212750 µg1:20040.02441 ± 0277 ± 1320.01412950 µg1:20150.024121 ± 124336 ± 00.013[^4][^5][^6][^7]

Relationship between serum antibody concentrations determined by passive protection, ELISA, and surface binding {#s0002-0002}
---------------------------------------------------------------------------------------------------------------

We next compared activity in the passive protection model with the anti-PcpA and anti-PhtD antibody concentrations determined by ELISA ([Table 2](#t0002){ref-type="table"}). Survival at day 4 tended to correspond with higher antibody concentrations ([Fig. 1A](#f0001){ref-type="fig"}). The ED50 for anti-PcpA IgG was estimated to be 9310 EU/ml (95% CI, 7318--11843) by logistic regression analysis ([Fig. 1B](#f0001){ref-type="fig"}). An ED50 could not be estimated for the anti-PhtD antibody because of a lack of fit to the logistic regression model ([Fig. 1C](#f0001){ref-type="fig"}). Table 2.Antibody concentrations and surface binding titres.  Anti-PcpA IgG(EU/ml)Anti-PhtD IgG(EU/ml)Surface binding titer (1/dilution)Vaccine DoseSubject no.Pre-immune serumPost-immune serumFold differencePre-immune serumPost-immune serumFold differencePre-immune serumPost-immune serumFold difference10 µg1019882053010.34656812.37613171602.3 231780157478.863121063.38542154301.825 µg6111142106318.922816627.37868189222.4 702017181789.0925506.09044165431.8 8023075301523.0674977.412234416593.4 845438208353.85616931.215127204171.3 9423532651611.33526401.86734182982.7 1014829149853.1762983.99725163741.7 1058111350684.31938524.410936278252.550 µg10819397377738.02428913.710936431393.9 1104740285366.06409321.59186181152.0 1127626210012.8574808.411208109511.0 1155846198553.41542431.68300116491.4 11744076024913.753118353.57564301564.0 1216614414056.3953573.87417234963.2 1222991277159.3484739.94466156973.5 1235048405998.017112647.410539241562.3 12441375303312.813613089.612544373573.0 12711517021461.01056616.33484309488.9 1295029166033.34035821.410112163421.6[^8]

We also compared activity in the passive protection model with the extent of bacterial surface binding by serum antibodies. For 19 of 20 subjects, bacterial surface binding was greater for the post-immune serum than for the pre-immune serum (range, 1.3--8.9) ([Table 2](#t0002){ref-type="table"}). Correlations between surface binding and antibody concentration were statistically significant for both antibodies, but the correlation was stronger for anti-PcpA (0.87; p \< 0.0001) than for anti-PhtD (0.71; p \< 0.0001).

Survival at day 4 could be predicted by both ELISAs as well as by bacterial surface binding. However, the odds ratio for predicting survival was higher with the anti-PcpA IgG ELISA (470 \[95% CI, 46.8 to \> 999.9\]) than with the anti-PhtD IgG ELISA (3.4 \[95% CI, 1.9 to 5.6\]) or the surface binding assay (9.4 \[95% CI, 3.6 to 24.3\]).

Functional activity using S. pneumoniae strain WU2 in place of strain A66.1 {#s0002-0003}
---------------------------------------------------------------------------

To explore the role of anti-PhtD antibody in more detail, we examined passive protection against *S. pneumoniae* strain WU2, which produces more PhtD than strain A66.1 when grown in the same low-Mn^2+^ medium (data not shown). For these experiments, samples were pooled from 4 subjects whose post-immune serum had high activity in the standard (strain A66.1) passive protection model. Protection from death was dose-dependent ([Fig. 2A](#f0002){ref-type="fig"}). At a dilution of 1:40, the pooled pre-immune serum protected no mice (0/5), whereas the pooled post-immune serum protected 100% (5/5). Figure 2.Protection of mice in the passive protection model using strain WU2. Sera from subjects 10, 121, 122, and 124 were pooled and tested in the murine passive protection model using serotype 3 strain WU2 in place of strain A66.1. (A) Pooled pre- and post-immune sera were first tested at 1:20 to 1:160 (5 mice/group) to identify a dilution where the pre-immune pooled serum did not provide protection. Shown is the number of mice surviving at day 10. (B) Pooled pre- and post-immune serum were tested at a dilution of 1:40 (15 mice/group). To test specificity, pooled post-immune serum was pre-incubated for 1 h with no addition, 400 µg/ml PcpA, 400 µg/ml PhtD, or both before testing in the passive protection model. Shown is the proportion surviving at each day up to day 10.

To examine the specificity of this protection, the pooled sera were pre-incubated with recombinant PcpA or PhtD. Pre-incubation with PcpA or PhtD reduced protection equally, and the combination of the 2 recombinant proteins eliminated protection ([Fig. 2B](#f0002){ref-type="fig"}).

Discussion {#s0003}
==========

This study showed that human antibodies induced by a bivalent PcpA-PhtD candidate vaccine are functional as indicated by their activity in an established mouse passive protection model. We previously used the same passive protection model to show that human antibodies induced by a monovalent PhtD candidate vaccine are functional.[@cit0020] A trivalent vaccine containing PhtD, PcpA, and detoxified pneumolysin has also been shown to protect infant mice against nasal challenge with a lethal dose of *S. pneumoniae* serotype 6A and 3.[@cit0025]

Passive protection is used to measure the potential functional activity of antibodies induced by pneumococcal protein vaccines, but passive protection assays are too cumbersome and time-consuming for screening large numbers of samples. We therefore examined whether the ELISA titer or surface binding activity could be used as a surrogate for functional activity, with the aim of simplifying testing and allowing for high-throughput screening, while reducing the need for animal testing. Both anti-PcpA and anti-PhtD antibody concentrations and surface binding activity correlated with passive protection in the mouse model, although the anti-PcpA concentration was the most predictive. The fact that the anti-PcpA concentration correlated better with passive protection than anti-PhtD suggests that the anti-PcpA antibodies played a more important role in protection, but this may have been due to the specific challenge strain used (A66.1). In fact, when we replaced strain A66.1 with WU2, which expresses higher levels of PhtD, we found that anti-PcpA and anti-PhtD antibodies contributed equally to the passive protection activity. Also, the results showed that the surface binding assay could be useful, at least as a secondary assay, for testing clinical trial samples for the presence of functional antibodies. Surface binding of antibodies is the initial step to subsequent opsonophagocytosis, but we did not measure opsonophagocytosis in the current investigation.

This study confirms our previous findings that vaccine-induced anti-PhtD antibodies are functional.[@cit0020] Similarly, Verhoeven et al. reported that immunization with monovalent PhtD and PcpA candidate vaccines protected infant and adult mice and improved bacterial clearance and survival following an intranasal challenge with *S. pneumoniae* serotype 6A.[@cit0017] Conversely, Kaur et al. found that vaccine-induced anti-PhtD but not anti-PcpA antibodies protected infant mice against colonization following an intranasal inoculation of *S. pneumoniae* serotype 4.[@cit0014] Our findings suggest that these differences may be related to the specific bacterial strains used, although other factors may also be involved, including differences in the route and site of infection, the route of serum administration, or the age and strain of the mice.

We used serotype 3 strain A66.1 for our initial experiments because it was previously used in mouse passive protection studies to test human clinical trial sera.[@cit0026] We added serotype 3 strain WU2, which has been used in passive protection studies to test monoclonal antibodies, because of its higher expression of PhtD.[@cit0027] Using these 2 serotype 3 strains, we showed that both the anti-PcpA and the anti-PhtD antibodies induced by the bivalent candidate vaccine protect mice against *S. pneumoniae*, information that can help in the development of a pneumococcal protein vaccine. These results highlight the benefits of using more than one functional model or at least more than one pneumococcal strain in evaluating the functional activity of vaccine-induced antibodies. Finally, we showed that anti-PcpA ELISA titres might be a useful surrogate for estimating the functional activity of antibodies induced by pneumococcal protein vaccines.

Materials and methods {#s0004}
=====================

Sera {#s0004-0001}
----

Sera tested in this study were from a phase I trial in which adults 18--50 y of age were vaccinated twice, 30 d apart, with an aluminium-adjuvanted PcpA-PhtD vaccine containing 10, 25, or 50 µg/antigen (ClinicalTrials.gov no. NCT01444339).[@cit0024] Sera were stored at −20°C and were heated to 56°C for 30 min to inactivate complement components.

Bacteria {#s0004-0002}
--------

*S. pneumoniae* serotype 3 strains A66.1 and WU2 were from D. Briles, University of Alabama-Birmingham, USA. Bacteria were grown in Todd Hewitt Broth with 0.5% yeast extract adjusted to pH 7 with MOPS. Because expression of PcpA is repressed by Mn^2+^,[@cit0023] the medium was depleted of metals using a Chelex-100 column (Bio-Rad, Hercules, CA, USA) and then adjusted to 1 mM FeSO~4~, 1 mM CaCl~2~, 1 mM MgCl~2~, 1 mM ZnCl~2~, and 0.1 µM MnSO~4~.

Recombinant proteins {#s0004-0003}
--------------------

Pneumococcal proteins PhtD and PcpA were cloned from strain 14453 (serotype 6B) and expressed in *Escherichia coli* as soluble proteins lacking their secretion signals. The choline-binding domain was also deleted from PcpA in the construct. The proteins were purified to ≥ 90% purity by ion-exchange chromatography as described previously.[@cit0024]

Passive protection assay {#s0004-0004}
------------------------

Mouse passive protection assays were performed as described previously.[@cit0020] Briefly, sera were diluted in phosphate-buffered saline and passively transferred by intraperitoneal injection to 6- to 8-week-old female CBA/CaHN-Btk xid /J (CBA/N) mice, a model of human X-linked immunodeficiency (Sanofi, Montpellier, France or Jackson Laboratories, Bar Harbor, ME, USA). Except where indicated, 5 mice were tested per condition. One hour after passive transfer, the mice were challenged by intravenous injection with a lethal dose of *S. pneumoniae* strain serotype 3 A66.1 (50 colony forming units) or strain WU2 (600 colony forming units). Survival was monitored for 14 d. Technicians performing the passive protection assays were blinded to the serum antibody concentration (determined by ELISA) and the dose of PhtD-PcpA vaccine that had been administered in the clinical trial. For specificity experiments, pooled sera were diluted in phosphate-buffered saline containing no addition, 400 µg/ml PcpA, 400 µg/ml PhtD, or 400 µg/ml PcpA + 400 µg/ml PhtD and then incubated for 1 h at 37°C before passive transfer.

Enzyme-linked immunosorbent assay (ELISA) {#s0004-0005}
-----------------------------------------

Antigen-specific IgG concentrations were analyzed as described previously.[@cit0024] Briefly, ELISA plates coated with recombinant PhtD or PcpA were incubated with duplicate serial dilutions of test sera or human AB serum standard (Sigma, St. Louis, MO, USA). Bound antibody was detected using horseradish peroxidase-conjugated goat-anti-human IgG (Jackson ImmunoResearch, West Grove, PA, USA) followed by tetramethylbenzidine substrate (Sigma-Aldrich, St. Louis, MO, USA). Antibody concentrations were determined by comparison with the human AB serum standard curve. The lower limit of quantitation was 0.123 ELISA units (EU)/ml for PhtD and 1.11 EU/ml for PcpA.

Antibody surface binding assay {#s0004-0006}
------------------------------

Serum samples were diluted to 1:50 in IF buffer (phosphate-buffered saline + 1% bovine serum albumin) and then serially diluted (5-fold dilutions) in the same buffer. Serum dilutions (20 µl/well) or buffer alone were added in duplicate to 96-well deep round-bottom plates (Ritter, Schwabmünchen, Germany) with 20 µl/well *S. pneumoniae* strain A66.1 suspended in IF buffer at 2.25 × 10^7^ colony forming units/ml. After incubation with shaking for 1 h at 37°C, plates were washed twice with IF buffer and incubated with shaking for 1 h with a 1:100 fluorescein isothiocyanate-conjugated rabbit F(ab\')~2~-anti-Human IgG H^+^L (Southern Biotech, Birmingham, AL, USA). After further washing with IF buffer, antibody surface binding was measured using a FC500 cytometer (Beckman Coulter, Villepente, France). The bacterial population was gated for forward and side scatter. The antibody titer was calculated using Softmax Pro (Molecular Devices, Sunnyvale, CA, USA) as the inverse of the dilution giving a X-mean 50.0 of 1.0.

Statistical analysis {#s0004-0007}
--------------------

Statistical analysis was performed using SAS version 9.1 (SAS Institute, Cary, NC). Differences in survival rates with pre- and post-immune sera were compared using logistic regression with logic link and a random subject effect. Time to death was assessed by Kaplan-Meier analysis and compared between groups by a one-sided Fisher exact test. The antibody concentration (in EU/ml) producing 50% survival (ED50) was estimated by logistic regression analysis with probit link and a random subject effect. Pearson correlation coefficients were calculated between activities for pairs of different in vitro assays (anti-PhtD ELISA, anti-PcpA ELISA, and surface binding). P \< 0.05 was considered to be statistically significant.
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======================

###### Supplementary files

Abbreviations
=============

CI

:   confidence interval

ELISA

:   enzyme-linked immunosorbent assay

EU

:   ELISA units

IF buffer

:   phosphate-buffered saline + 1% bovine serum albumin

PcpA

:   pneumococcal choline-binding protein A

PhtD

:   pneumococcal histidine triad protein D
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[^5]: ^a^P-value was determined by a one-sided Fisher exact test.
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[^8]: Anti-PcpA and anti-PhtD IgG concentrations were determined by ELISA. For surface binding, diluted sera were mixed with *S. pneumoniae* strain A66.1 for 1 h and then incubated with fluorescein isothiocyanate-conjugated rabbit F(ab\')~2~-anti-human IgG H^+^L, after which fluorescence was detected by flow cytometry.
